ISRCTN64649191已完成不适用
Acute myeloid leukaemia (AML) trial 12 (protocol for children)
Medical Research Council (MRC) (UK)0 个研究点目标入组 2,000 人开始时间: 2000年10月25日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 2,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. They have one of the types of acute myeloid leukaemia (de novo or secondary)
- •2. They have aggressive myelodysplastic syndrome (MDS) (Refractory anemia with excess blasts [RAEB], Refractory anemia with excess blasts in transformation [RAEB-t]) for whom AML-type therapy is considered appropriate
- •3. They are considered suitable for intensive chemotherapy
- •4. They are under 16 years and if the patients/parents have given informed consent
排除标准
- •1. Patients who have previously received cytotoxic chemotherapy for leukaemia;
- •2. They are in blast transformation of chronic myeloid leukaemia;
- •3. They have a concurrent active malignancy or the physician and patient/parents consider that intensive therapy is not an appropriate option.
研究者
相似试验
已完成
不适用
Acute Myeloid Leukaemia (AML) Trial 12 (modified) for patients aged under 60eukaemia (acute)LeukaemiaCancerISRCTN55678797Medical Research Council (MRC) (UK)500
已完成
不适用
Acute lymphoblastic leukaemia (ALL) trial XII (joint trial with Eastern Co-operative Oncology Group - E2993)eukaemiaCancerLeukaemiaISRCTN77346223Medical Research Council (MRC) (UK)550
已完成
不适用
AML 12 - Acute myeloid leukaemia Adults (modified)CancerISRCTN17833622Medical Research Council (MRC) (UK)
进行中（未招募）
3 期
Clinical Trial for the treatment of acute myeloid leukaemia in children and adolescentsC92.0Acute myeloblastic leukaemia [AML]DRKS00022788GPOH gemeinnützige GmbH AML-BFM Studienzentrale164
招募中
2 期
AMLM22/D2-The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in subjects with acute myeloid leukaemia in first complete remission. Domain 2 is investigating the safety and efficacy of Venetoclax as a maintenance therapy alone or in combination with low dose cytarabine (LDAC).Acute Myeloid Leukaemia (AML)Cancer - Leukaemia - Acute leukaemiaACTRN12619000280101Australian Leukaemia and Lymphoma Group (ALLG)75